InvestorsHub Logo
Followers 55
Posts 13535
Boards Moderated 0
Alias Born 10/12/2006

Re: LocWolf post# 17892

Monday, 11/13/2023 10:27:32 PM

Monday, November 13, 2023 10:27:32 PM

Post# of 18304
I blame HDC for not doing more with the patents by creating new products of their own. They did try a few times and failed. For example, that mobile app they created to identify skin cancer never went anywhere. And that silly attempt to create stock portfolios based on SVM caused more trouble than it was worth.

However, I think the much bigger lost opportunity was an inability to license the technology to much larger companies with huge revenues from existing products that already utilized SVM. I blame Intel for that lost opportunity. It is extremely likely that the ongoing legal battles with Intel prevented some or most companies from agreeing to a licensing deal. Neogenomics did agree to license the technology but they are probably the exception. Even with Neogenomics choosing to license the tech, many other companies may have decided to wait until the outcome of the legal battle with Intel was known. Also, if I recall correctly, Neogenomics and HDC treated the arrangement more as a partnership with a shared expert - was it Dr Albitar? - working on the product.

I also don’t know if we ever found out why the biomarker test with Quest never panned out as expected. Did the patent dispute put that test on ice? I can’t remember so I could be wrong. I just remember that we had a superior prostate cancer test but for some reason Quest never rolled it out.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HDVY News